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Background: Interactions between fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) regulate microglial
activation in the CNS. Recent findings indicate that age-associated impairments in CX3CL1 and CX3CR1 are directly
associated with exaggerated microglial activation and an impaired recovery from sickness behavior after peripheral
injection of lipopolysaccharide (LPS). Therefore, the purpose of this study was to determine the extent to which an




-/- mice or control heterozygote mice (CX3CR1
+/-) were injected with LPS (0.5 mg/kg i.p.) or saline
and behavior (i.e., sickness and depression-like behavior), microglial activation, and markers of tryptophan
metabolism were determined. All data were analyzed using Statistical Analysis Systems General Linear Model
procedures and were subjected to one-, two-, or three-way ANOVA to determine significant main effects and
interactions.
Results: LPS injection caused a prolonged duration of social withdrawal in CX3CR1
-/- mice compared to control
mice. This extended social withdrawal was associated with enhanced mRNA expression of IL-1b, indolamine 2,3-
dioxygenase (IDO) and kynurenine monooxygenase (KMO) in microglia 4 h after LPS. Moreover, elevated expression
of IL-1b and CD14 was still detected in microglia of CX3CR1
-/- mice 24 h after LPS. There was also increased
turnover of tryptophan, serotonin, and dopamine in the brain 24 h after LPS, but these increases were
independent of CX3CR1 expression. When submitted to the tail suspension test 48 and 72 h after LPS, an increased
duration of immobility was evident only in CX3CR1
-/- mice. This depression-like behavior in CX3CR1
-/- mice was
associated with a persistent activated microglial phenotype in the hippocampus and prefrontal cortex.
Conclusions: Taken together, these data indicate that a deficiency of CX3CR1 is permissive to protracted microglial
activation and prolonged behavioral alterations in response to transient activation of the innate immune system.
Background
Microglia are myeloid derived cells that play a key role
in immune surveillance of the central nervous system
(CNS) [1,2]. Together with brain macrophages these
cells interpret and propagate inflammatory signals in
response to activation of the peripheral immune system
[3]. Activated microglia produce pro-inflammatory
cytokines and secondary messengers which elicit a sick-
ness behavior syndrome [4]. While this sickness
response is normally adaptive, amplified or prolonged
microglial activation is associated with a myriad of beha-
vioral and cognitive complications [5]. Therefore, tight
regulation of microglial activation is necessary to limit
cytokine production and maintain a transient neuroin-
flammatory response.
One mechanism of microglial regulation involves inter-
actions between fractalkine (CX3CL1) and fractalkine
receptors (CX3CR1) [6,7]. Complementary expression of
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establishes a unique communication system whereby neu-
rons constitutively express and release CX3CL1 to regu-
late activation of microglia [10]. For example,
pretreatment with neutralizing anti-CX3CL1 antibody
exaggerates TNFa and 8-isoprostane production after
intracerebroventricular (i.c.v.) injection of lipopolysac-
charide (LPS) [11]. In cultured microglia or mixed glial
cultures, soluble CX3CL1 attenuates LPS-induced produc-
tion of TNFa, IL-6, and IL-1b [12,13]. Moreover,
CX3CR1-deficiency amplifies microglial IL-1b expression
and neurotoxicity in CX3CR1
-/- mice compared to
CX3CR1
+/- mice after repeated i.p. injections of lipopoly-
saccharide (LPS) [10].
Recent work using rodent models of aging also sup-
port the premise that impaired CX3CL1/CX3CR1 inter-
actions cause increased microglial activation. For
example, CX3CL1 mRNA and protein are decreased in
the brain of aged rats [14,15] and mice [5]. This age-
associated increase in activated (e.g., MHC II
+) microglia
was attenuated following a single i.c.v. injection of
CX3CL1 [15]. In a related experiment, infusion of a neu-
tralizing antibody to CX3CR1 increased the number of
MHC II
+ microglia in young rats [14]. Along with
reductions in brain levels of CX3CL1, regulation of
CX3CR1 expression on the surface of microglia may
also be impaired in the aged brain. In comparisons
between adult and aged mice, CX3CR1 surface expres-
sion was decreased on microglia after peripheral injec-
tion of LPS. In aged mice, however, the LPS-induced
downregulation of CX3CR1 on microglia was protracted
a n dc o r r e s p o n d e dw i t ha m p l i f i e dI L - 1 b levels in micro-
glia and impaired recovery from sickness behavior [5].
Collectively, these data indicate that CX3CL1-CX3CR1
interactions are important in normal regulation of
microglia and become dysregulated with age.
Clinical and experimental data indicate that there is a
cause/effect relationship between inflammation and
depression [16,17]. In animal models, proinflammatory
cytokine production (e.g., IL-1b, IL-6, or TNFa) follow-
ing systemic LPS challenge [18-20], chronic infection
with Bacillus Calmette-Guerin (BCG) [21,22], stroke
[23], or psychological stress [24-26] cause depression-
like behavior. One potential mechanism by which
inflammatory cytokines promote depression-like beha-
vior is through the activation of the tryptophan degrad-
ing enzyme indoleamine 2,3-dioxygenase (IDO) [21,27].
Active IDO converts tryptophan (TRP) into kynurenine
(KYN). In microglia [28], KYN is processed by kynure-
nine monooxygenase (KMO), which produces two
highly neuroactive mediators, 3-hydroxykynurenine
(3HK) and quinolinic acid (QUIN) [29]. IDO activity
and downstream processing of KYN have been shown
to cause inflammatory-associated depression in rodent
models [20,22]. It is hypothesized that IDO activation is
a key mechanism underlying mood and depressive com-
plications because it alters serotonergic, dopaminergic,
and noradrenergic neurotransmission [4,17,30,31].
Because CX3CL1 and CX3CR1 interactions are
impaired in the brain of aged rodents [5], we hypothe-
size that a loss of CX3CR1 may be permissive to exag-
gerated microglial activation and the promotion of a
maladaptive sickness response after an innate immune
challenge. Therefore, the purpose of this study was to
determine the extent to which an acute LPS injection
causes amplified and prolonged microglial activation
and behavioral deficits in CX3CR1-deficient mice
(CX3CR1
-/-). Here we show that CX3CR1
-/- mice exhib-
ited prolonged social withdrawal and depression-like
behavior after LPS injection. These behavioral altera-




Adult (3-6 m) heterozygotes (CX3CR1
+/-)a n dh o m o z y -
gotes (CX3CR1
-/-) from our in-house specific pathogen
free colony were used. These CX3CR1 transgenic mice
were created in the background strain of C57BL/6 [32].
An EGFP cassette was inserted in place of the first 390
bp of the second exon of the gene for CX3CR1 that dis-
rupts the CX3CR1 gene and labels all cells that would
normally express CX3CR1 with a green fluorescent pro-
tein [32]. Mice were housed in polypropylene cages and
maintained at 25°C under a 12 h light/12 h dark cycle
with ad libitum access to water and rodent chow. All
procedures were in accordance with the National Insti-
tute of Health Guidelines for the Care and Use of
Laboratory Animals and were approved by The Ohio
State University Institutional Laboratory Animal Care
and Use Committee.
Behavior
Locomotor activity, social exploratory behavior, and res-
ignation behavior were determined as previously
described [19,20,33]. In brief, mice were acclimated to
routine handling 5 days before experimentation. Mice
were injected with 0.5 mg/kg LPS and behavioral testing
was assayed at the indicated times after injection. Beha-
vioral tests were conducted during the dark phase
(between 1200 and 2400) of the photoperiod under
infrared lighting. Behavior was scored by a trained
observer who was blind to the experimental treatments.
For locomotor activity, mice were maintained in their
home cage with a floor area of 26 × 20 cm, and activity
was video recorded for 3 minutes. On the video records,
cages were divided into 6 identical virtual rectangles and
the number of line crossings was determined.
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introduced into the test subject’s home cage for a
10-min period. Behavior was videotaped and the cumu-
lative amount of time the adult mouse engaged in social
investigation was determined.
For depression-like behavior, tail suspension test was
performed (TST). Mice were suspended by their tail in a
32 × 33 × 33 cm box and the duration of immobility
was determined over a 10 min period. In these experi-
ments, the mice were allowed to acclimate to the testing
parameters for 2 minutes prior to scoring the results.
Results are expressed as the total immobility for the last
8 minutes of the test.
IL-1b and CX3CL1 protein levels
IL-1b and CX3CL1 protein were determined in brain
and plasma samples as previously described [5,33]. In
brief, mice were anesthetized by CO2 inhalation and
blood was collected by cardiac puncture. Blood was cen-
trifuged (4000 × g for 15 min at 4°C) and plasma was
collected and stored frozen (-80°C) until assaying. Brain
samples were homogenized in lysis buffer (50 mM Tris-
HCl pH 7.4, containing 10% glycerol, 1.0% Triton-X
100, 100 mM NaCl, 50 mM NaF, 1 mM EDTA, 1 mM
EGTA, 2 mM PMSF, and leupeptin, aprotinin, and pep-
statin at 1 μg/ml each), centrifuged (16,000 × g for 10
min at 4°C) and clarified lysates were assayed for total
protein content (Bio-Rad, Cambridge MA). IL-1b or
CX3CL1 concentration was determined in brain homo-
genates and plasma using commercial ELISA kits (R&D
Systems, Minneapolis, MN). Absorbance (450 nm) was
determined using a Bio-Tek synergy HT microplate
reader (Bio-Tek Instruments, VT). Assays were sensitive
to 1.5 pg/ml for IL-1b and 0.20 ng/ml for CX3CL1. For
both assays, inter- and intra-assay coefficients of varia-
tion were less than 10%.
Analysis of microglial gene expression and flow
cytometry
Microglia were isolated from whole brain homogenates
as previously described [5,34]. Brains were homogenized
in Hank’s Balanced Salt Solution (HBSS, pH 7.4) and
centrifuged. Microglia were isolated using discontinuous
Percoll density gradient (GE-healthcare, Uppsala,
Sweden). The population that was isolated was found to




Quantitative RT-PCR was performed using the
Applied Biosystems (Foster, CA) Assay-on-Demand
Gene Expression protocol as previously described [33].
In brief, RNA was isolated using the RNeasy plus mini
kit (Qiagen, CA) and reverse transcribed to cDNA using
an RT RETROscript kit (Ambion, TX). The target
cDNA (e.g., CD11b, IL-1b,I D O ,K M OT N F a,C D 1 4
and TLR2) and a reference cDNA (glyceraldehyde-3-
phosphate dehydrogenase) were amplified simulta-
neously. Data were analyzed using the comparative
threshold cycle (Ct) method and results are expressed as
fold difference from control.
Analysis of microglial surface antigens by flow cyto-
metry was performed as previously described [34,35]. In
brief, Fc receptors were blocked and microglia were
incubated with anti CD14 and CD45 antibodies
(eBioscience, CA). Antigen expression was determined
using a Becton-Dickinson FACSCaliber four color Cyt-
ometer. Ten thousand events were recorded. For each
antibody, gating was determined based on appropriate
negative isotype stained controls. Flow data were ana-
lyzed using FlowJo software (Tree Star, CA).
Neurochemistry
Tryptophan (TRP) and kynurenine (KYN) were deter-
mined as previously described [22]. In brief, plasma
samples were deproteinated with 10% sulfosalicylic acid
(5:1, v:v). Brain tissue was mechanically homogenized in
0.1N HClO4 +2 5μM ascorbate. Samples were precipi-
tated on ice for 30 min and centrifuged at 12,000 × g
for 10 minutes at 4°C. The resulting supernatants were
loaded into a Costar Spin-X centrifuge tube filter (0.22
μM Nylon Part #8169 Corning Incorporated) and centri-
fuged at 12,000 × g for 6 minutes at 4°C. Levels of tryp-
tophan (TRP) and kynurenine (KYN) in the plasma and
brain were determined using an ESA Coulochem III
detector with a 5041 Enhanced Analytical cell contain-
ing a glassy carbon electrode (+600 mV). Samples were
separated using a Mobile phase of 75 mM NaH2PO4,
25 μM EDTA-disodium salt, and 100 μl/L triethylamine
in acetonitrile:water (6:94 v:v; pH 4.6).
Monoamines and metabolites were analyzed in whole
brain as previously described [36]. Dopamaine (DA),
homovanillic acid (HVA), and 3,4 Dihydroxyphenylacetic
acid (DOPAC), serotonin (5-hydroxytryptophan; 5-HT)
5-hydroxyindoleacetic acid (5-HIAA), were analyzed at a
potential of +320 mV, and the mobile phase (pH = 3.0)
consisted of 75 mM NaH2PO4,2 5μM EDTA (disodium
salt), 1.7 mM octanesulfonic acid, and 100 μl/L triethy-
lamine in acetonitrile:water (6:94 v:v). The chromato-
grams were integrated and quantified using ESA EZ
Chrom SI software (ESA Inc., Chelmsford, MA).
Immunohistochemistry and digital image analysis
Mice were deeply anesthetized and transcardially per-
fused with sterile PBS followed by 4% formaldehyde.
Brains were post-fixed in 4% formaldehyde for 24 h and
then cryoprotected in 20% sucrose for an additional
24 h. Preserved brains were frozen using dry-ice cooled
isopentane (-165°C) and then sectioned (20 μm) using a
Microm HM550 cryostat. The brain sections were
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stereotaxic mouse brain atlas [37]. Sections were
mounted on microscope slides and stored at -20°C
before staining procedures. Iba1 staining was performed
as previously described [38]. In brief, sections were
blocked and then incubated with rabbit anti-mouse Iba-
1 antibody (Wako Pure Chemical Industries, Ltd., VA)
overnight at 4°C. Next, HRP-conjugated goat anti-rabbit
secondary antibody for 1 h at room temperature and
staining was developed using the Vector VIP kit (Vector
laboratories, CA).
For fluorojade-C staining, sections were prepared as
described above and then incubated with 1% NaOH in
ethanol and rinsed with 70% ethanol. Sections were
then incubated with 0.06% potassium permanganate
solution before incubation with 0.0001% fluorojade-C in
0.1% acetic acid. Slides were then washed with water
and air dried, cleared with histoclear, and mounted with
permount.
Fluorescent and brightfieldi m a g e sw e r ev i s u a l i z e d
using an epifluorescent Leica DM5000B microscope.
Images were captured using a Leica DFC300 FX camera
and imaging software. To quantify the phenotypic
changes of microglia, digital image analysis (DIA) of
Iba1 staining was performed [39] in the hippocampus
(-.1.7 to -2.3 mm bregma), basolateral amygdala (-1.7 to
-2.06 mm bregma), and prefrontal cortex (+2.34 to
+1.98 mm bregma) for each sample. To determine Iba1
phenotype in the entire hippocampus, at least three
representative images were taken at 20× magnification
in the dentate gyrus, CA1, and CA3 region of the hippo-
campus. For the basolateral amygdala and prefrontal
cortex, at least 6 representative pictures were analyzed.
A threshold for positive staining was determined for
each image that included all cell bodies and processes,
but excluded background staining. Thresholded targets
were analyzed using densitometry and ImageJ software.
Results were reported as the average percent area in the
positive threshold for all representative pictures.
Statistical Analysis
To ensure a normal distribution, data were subjected to
Shapiro-Wilk test using Statistical Analysis Systems
(SAS) software (Cary, NC). Observations greater than 3
interquartile ranges from the first and third quartile
were considered outliers and were excluded in the sub-
sequent analysis. To determine significant main effects
and interactions between main factors, data were ana-
lyzed using one- (Genotype, Treatment, Time), two-
(Genotype × Treatment, Treatment × Time) or three-
(Genotype × Treatment ×Time) way ANOVA using the
General Linear Model procedures of SAS. When appro-
priate, differences between treatment means were evalu-
ated by an F-protected t-test using the Least-Significant
Difference procedure of SAS. All data are expressed as
treatment means ± standard error of the mean (SEM).
Results
Exaggerated social withdrawal after LPS injection in
CX3CR1
-/- mice
To begin to explore the hypothesis that CX3CR1-defi-
cient mice have significant behavioral complications
after transient activation of the innate immune system,
motivation to engage in social exploratory behavior was
assessed. In this experiment, behavior was determined
in CX3CR1
+/- (Control) and CX3CR1
-/- (KO) mice prior
to i.p. injection of LPS and again 4, 8, 12, and 24 h after
treatment. LPS injection exaggerated social withdrawal
in CX3CR1
-/- mice compared to control mice (genotype
× LPS interaction, F(1,149) = 16.35, P < 0.0001). This
exaggerated social withdrawal in CX3CR1
-/- mice after
LPS was dependent on time (tendency for genotype ×
LPS × time interaction, F(4,149) = 2.32, P = 0.06). For
example, CX3CR1
-/- mice had an 87.2 ± 5.2% reduction
in social exploration at 8 h after LPS while control mice
had only a 52.7 ± 10.5% reduction (P <0 . 0 0 1 ) .F u r t h e r -
more, control mice recovered to baseline social behavior
by 24 h after injection, but CX3CR1
-/- mice had not
recovered (P < 0.001). Taken together, these data indi-
cate that LPS caused a prolonged reduction in social
exploratory behavior in CX3CR1
-/- mice compared to
CX3CR1
+/- controls.
Food intake and change in body weight were also
determined over the 24-h period after LPS injection.
Because there was not a significant interaction between
genotype and LPS, these data were collapsed to show the
main effect of LPS. LPS injection caused a significant
reduction in food intake (Figure 1B; F(1,29) = 118.9, P <
0.0001) and body weight (Figure 1C; F(1,29) = 199.5, P <
0.0001) that did not differ according to genotype.
Higher levels of IL-1b protein in the cortex and plasma in
CX3CR1
-/- mice after LPS injection
The pro-inflammatory cytokine, interleukin (IL)-1b is a
key cytokine in the induction of sickness behavior
[40,41]. Therefore, IL-1b protein levels were determined
in the brain and plasma of control and CX3CR1
-/- mice
4 h after LPS injection. Figure 2A shows LPS injection
increased IL-1b protein in the cortex (F(1,17) = 6.95,
P < 0.05) and that IL-1b protein levels were highest in
the cortex of CX3CR1
-/- mice compared to all other
treatment groups (P < 0.05). Plasma levels of IL-1b were
also increased by LPS injection (F(1,17) = 43.92, P <
0.0001) and these levels were higher in CX3CR1
-/- mice
than in all other groups (Figure 2B; genotype × LPS
interaction, F(1,17) = 8.38, P < 0.05).
A previous study showed that CX3CR1
-/- mice have
significantly higher levels of CX3C L 1i nt h eb r a i na n d
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http://www.jneuroinflammation.com/content/7/1/93
Page 4 of 14plasma than control mice [42]. It is not known if
CX3CL1 protein levels are changed in CX3CR1
-/- mice
during a transient sickness response induced by LPS.
Furthermore, increases in CX3CL1 protein in the brain
after LPS injection could be involved in recruiting per-
ipheral immune cells to the brain [43-45]. Therefore,
total CX3CL1 protein was determined in the cortex and
plasma. Levels of CX3CL1 were higher in the plasma
and cortex of CX3CR1
-/- mice (Figure 2C &2D, main
effect of genotype, F(1,15) = 230.82, P <0 . 0 0 0 1a n dF
(1,15) = 57.12, P < 0.0001, respectively). Consistent with
a previous study using adult (3-4 mo) and aged
(18-24 mo) Balb/c mice [5], CX3CL1 levels were not
increased by LPS injection.
Increased microglial mRNA expression of IL-1b, IDO and
KMO in CX3CR1
-/- mice 4 h after LPS injection
Because IL-1b levels were highest in the cortex of
CX3CR1
-/- mice after LPS injection, the contribution of
microglia to these exaggerated IL-1b levels was assessed.
In this experiment, adult CX3CR1
+/- and CX3CR1
-/-
mice were injected i.p. with LPS and mRNA levels of
several inflammatory-related genes, IL-1b,T N F a,T L R 2 ,
CD14, and CD11b were determined in enriched micro-
glia collected 4 h later. Figure 3A shows that IL-1b,
TNFa, TLR2, CD14, and CD11b mRNA expression in
enriched microglia was increased 4 h after peripheral
LPS injection (Figure 3A-E; main effect of LPS, P <0 . 0 1
for each) and this LPS-induced increase was more
marked in microglia of CX3CR1
-/- mice for IL-1b,o n l y
(genotype × LPS interaction, F(1,31) = 3.24, P = 0.08).
The mRNA levels of IDO and KMO, two genes asso-
ciated with metabolism of tryptophan [4] were also
determined. IDO activity is an important mediating fac-
tor in depression-like behavior after LPS injection in
C57B/6 mice [20]. Furthermore, downstream processing
of KYN by KMO into neuroactive metabolites is linked
with depression in human patients undergoing IFN-
alpha stimulation [46]. IDO mRNA was higher in micro-
glia of LPS-treated CX3CR1
-/- mice than microglia
of LPS-treated control mice (Figure 3F; F(1,19) = 2.9,
Figure 1 LPS injection caused exaggerated social withdrawal in
CX3CR1
-/- mice.A )C X 3CR1
+/- (Control) or CX3CR1
-/- (KO) mice were
injected i.p. with saline or LPS (0.5 mg/kg) and social exploratory
behavior was measured before LPS injection and again 4, 8, 12 and
24 h later. Graph represents the mean ± SEM (n = 10). Means with *
are significantly different (P < 0.05) from respective saline-treated
controls and means with ‡ are significantly different from Control
LPS. B) Body weight and C) food intake were determined before i.p.
LPS injection and again 4, 8, 12, and 24 h later. Because there was
no significant effect of genotype, data were collapsed to show the
main effect of LPS. Bars represent the mean ± SEM (n = 10). Means
with * are significantly different (P < 0.05) from saline controls.
Figure 2 LPS injection caused an exaggerated increase in IL-1b
in the brain and plasma of CX3CR1
-/- mice.C X 3CR1
+/- (Control) or
CX3CR1
-/- (KO) mice were injected i.p. with saline or LPS (0.5 mg/kg)
and IL-1b protein levels determined in the A) cortex and B) plasma
collected 4 h after injection. Bars represent the mean ± SEM. Means
with different letters (a, b, or c) are significantly different (P < 0.05)
from each other. In a related study, mice were treated as above and
CX3CL1 protein levels were determined in the C) cortex and D)
plasma collected 4 h after injection. Bars represent the mean ± SEM.
Means with different letters (a, b, or c) are significantly different (P <
0.05) from each other
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(1,38) = 20.9, P < 0.0001) and genotype (F(1,38) = 4.75,
P < 0.05) with the highest levels in the microglia
of CX3CR1
-/- mice that received LPS (P < 0.05). Collec-
tively, these data indicate that microglia of CX3CR1-
deficient mice have exaggerated RNA induction
of IL-1b,I D O ,a n dK M Oc o m p a r e dt ot h eC X 3CR1
+/-
control mice 4 h after LPS injection.
Prolonged microglial expression of IL-1b in CX3CR1
-/-
mice 24 h after LPS injection
The key issue with a deficiency in CX3CR1 surface
expression may be associated with the duration that the
microglia are actively producing cytokines [47]. There-
fore, several inflammatory-related genes (IL-1b,T N F a,
TLR2, CD14, and CD11b) and TRP metabolism-related
genes (IDO and KMO) were determined 24 h after LPS
Figure 3 Amplified IL-1b IDO and KMO mRNA induction in microglia of CX3CR1
-/- mice following peripheral LPS injection.C X 3CR1
+/-
(Control) or CX3CR1
-/- (KO) mice were injected i.p. with saline or LPS (0.5 mg/kg) and A) IL-1b, B) TNFa, C) TLR2, D) CD14, E) CD11b, F) IDO and
G) KMO mRNA levels determined from enriched microglia isolated 4 h after LPS injection. Bars represent the mean ± SEM. n.d. = values were
non-detectable. Means with different letters (a, b, or c) are significantly different (P < 0.05) from each other.
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still significantly elevated in microglia of CX3CR1
-/- mice
compared to controls (genotype × LPS interaction, F
(1,27) = 10.06, P < 0.01). TLR2 tended to be significantly
elevated in microglia of CX3CR1
-/- mice compared to
microglia of control mice (Figure 4B; genotype × LPS
interaction, F(1,28) = 4.35, P =0 . 0 9 ) .C D 1 4m R N Aw a s
induced 24 h after LPS in CX3CR1
-/- (main effect of
LPS, F(1,15) = 5.7, P < 0.05), but was unchanged in con-
trol mice after LPS (Figure 4C). Similar to the mRNA
Figure 4 Prolonged IL-1b, TLR2 and CD14 expression in microglia of CX3CR1
-/- mice following peripheral LPS injection.C X 3CR1
+/-
(Control) or CX3CR1
-/- (KO) mice were injected i.p. with saline or LPS (0.5 mg/kg) and A) IL-1b, B) TNFa, C) TLR2, D) CD14 mRNA and E) CD11b
levels were determined in enriched microglia isolated 24 h after LPS injection. Bars represent the mean ± SEM. Means with different letters (a, b,
or c) are significantly different (P < 0.05) from each other. In a related study, control or KO mice were injected i.p. with saline or LPS and surface
expression of CD14 protein on microglia was determined. F) Representative histograms of CD14 expression on microglia following experimental
treatments. G) Mean fluorescence Intensity (M.F.I.) of CD14 expression on microglia (GFP
+/CD45
low) following experimental treatments. Bars
represent the mean ± SEM (n = 6). Means with different letters (a, b, or c) are significantly different (P < 0.05) from each other.
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mRNA levels were increased by LPS, but these increases
were independent of the CX3CR1 expression (Figure
4B&4D). LPS-induced increases in the mRNA levels of
I D Oa n dK M Oi nm i c r o g l i aw e r en o td e t e c t e da tt h i s
24 h time point (data not shown).
Because protein expression may not always coincide
with mRNA transcription, a subset of mice were
injected with saline or LPS and CD14 protein expression
was determined on GFP
+/CD45
low microglia 24 h later.
Representative histograms of CD14 staining of microglia
are shown in Figure 4F. LPS increased surface expres-
sion of CD14 on microglia (main effect of LPS, F(1,21)
= 17.83, P < 0.001), and CD14 expression was the high-
est on microglia from LPS treated CX3CR1
-/- mice com-
pared to all other treatment groups (P <0 . 0 5 ) .T a k e n
together these data indicate that a specific subset of
LPS-induced inflammatory markers are elevated longer
in microglia of CX3CR1
-/- mice than in control mice.
Increased turnover of TRP in the brain and plasma after
LPS
IDO is a key pathway in metabolism of TRP into KYN,
and is involved in the induction of inflammatory-
mediated depression in rodent models. Thus, the ratio
of KYN to TRP is an accepted measure of IDO enzy-
matic activity [20,22]. Because there was an initial
amplified induction of IDO in CX3CR1
-/- mice (Figure
3F&3G), KYN and TRP levels were determined in
plasma and brain of control and CX3CR1
-/- mice 24 h
after LPS injection. Although LPS injection significantly
increased the ratio of KYN to TRP, there was not a sig-
nificant interaction between genotype and LPS at this
time point. For this reason, the data were collapsed to
show the main effect of LPS treatment. Figure 5A shows
that the ratio of KYN/TRP in the brain tended to be
higher in LPS-injected mice compared to saline injected
mice (F(1,29) = 4.02, P = 0.06). LPS also significantly
increased the KYN/TRP ratio in the plasma (Figure 5A;
F(1,29) = 13.6, P < 0.001).
Because proinflammatory cytokines directly alter the
levels of monoamines and their metabolites [48], levels
of serotonin (5-HT), 5-hydroxyindoleacetic acid (5-
HIAA), dopamine (DA), homovanillic acid (HVA) and
3,4 Dihydroxyphenylacetic acid (DOPAC), were deter-
m i n e di nt h eb r a i n2 4ha f t e rL P Si n j e c t i o n .F i g u r e5 B
shows that LPS injection markedly increased the ratio of
5-HIAA to 5-HT (F(1,31) = 41.48, P < 0.0001). LPS also
i n c r e a s e dt h er a t i oo fD At oH V A( F i g u r e5 C ;F ( 1 , 3 1 )=
9.96, P < 0.01), but did not increase the ratio of DOPAC
to DA (Figure 5D). In all cases, the increased ratio was
related to an increase in the concentration of the meta-
bolite (data not shown). Taken together these data indi-
cate that there is increased metabolism of TRP, 5-HT
and DA in the plasma and brain 24 h after LPS injection
that is independent of CX3CR1 expression.
Prolonged depression-like behavior detected only in
CX3CR1
-/- mice after LPS
We have previously reported that peripheral stimulation
of the innate immune system with LPS in aged BALB/c
mice (22-24 mo) causes prolonged sickness [33] and
depression-like behaviors [19]. These behaviors are
coupled with exaggerated microglial activation [35] and
impaired CX3CR1-mediated regulation of microglia [5].
Based on these data, we next sought to determine the
degree to which the depression-like behavior was evi-
dent in CX3CR1
+/- and CX3CR1
-/- mice after LPS injec-
tion. Depression-like behavior was assessed using the
tail suspension test (TST), which is an assessment of
motivation and resignation behavior in mice [19,49]. In
this experiment, mice were injected with LPS and loco-
motor activity and resignation behavior were deter-
mined. Figure 6A shows that LPS caused a time-
dependent reduction in locomotor activity (LPS × time
interaction, F(3,152) = 2.84, P < 0.05) that was indepen-
dent of genotype. All LPS-treated mice returned to
Figure 5 LPS injection caused increased turnover of TRP, 5-HT,
and DA.C X 3CR1
+/- (Control) or CX3CR1
-/- (KO) mice were injected i.
p. with saline or LPS (0.5 mg/kg). Because there was no significant
effect of genotype, data were collapsed to show the main effect of
LPS. A) The ratio of KYN to TRP was determined in the brain and
plasma 24 h later. B) The ratio of 5-HIAA to 5-HT, C) the ratio of
HVA to DA, D) the ratio of DOPAC to DA were determined in the
brain 24 h later. Bars represent the mean ± SEM. Means with * are
significantly different (P < 0.05) from saline controls.
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Therefore, behavior was determined at 48 and 72 h.
These two time points correspond with a time when
mice were recovering from LPS-induced changes in
locomotor activity (i.e., 48 h) and a time when they had
fully recovered (i.e., 72 h). Figure 6B shows that immo-
bility was increased after LPS (F(1,95) = 21.68, P <
0.0001) and that this increased resignation was only evi-
dent in LPS-treated CX3CR1
-/- mice (genotype × LPS
interaction, F(1,95), 4.36, P < 0.05). These data indicate
that LPS injection prolonged depression-like behavior in
only CX3CR1
-/- mice.
Activated microglial morphology is prolonged in
CX3CR1
-/- mice 72 h after LPS
We next sought to determine the degree to which pro-
longed resignation was associated with neuronal damage
and microglia activation. In these experiments, CX3CR1
+/- and CX3CR1
-/- mice were injected i.p. with LPS and
brains were collected 72 h after injection. To assess neu-
ronal damage, the presence of fluorojade-c positive cells
was determined. Brains of C57Bl/6 mice subjected to
pilocarpine-induced status epilepticus were used as a
positive control for neuronal damage [50]. (Figure 7A).
While there was increased Fluorojade-c positive staining
in the positive control in all of the examined brain
regions increased Fluorojade-c staining was not detected
in any of the other experimental groups (Figure 7A ii-v).
Representative pictures in the dentate gyrus region of
the hippocampus are shown. Neuronal damage was not
found in the basolateral amygdala and prefrontal cortex
in any experimental group (data not shown).
For the analysis of microglia activation, ionized cal-
cium binding adapter molecule 1 (Iba1) staining was
evaluated in the prefrontal cortex, basolateral amygdala,
and hippocampus 72 h after injection. These regions
were chosen because they are involved in mediating
depression-like behavior in humans [51] and in mouse
models [25]. Iba1 is an ideal marker for documenting
microglia morphology in intact and pathological tissues
[38]. Active microglia undergo hypertrophy and retract
their processes [52]. Representative images of Iba1
+
microglia from each region are shown in Figure 7B-D.
LPS-treated mice had larger cell bodies and thicker and
condensed processes in the prefrontal cortex (Figure 7B)
and the hippocampus (Figure 7D). In the prefrontal cor-
tex of LPS-treated mice, digital image analysis [39] indi-
cated that microglia had an increased proportional area
of Iba1 immunoreactivity compared with microglia from
saline-treated mice (Figure 7D; F(1,14) = 10.27, P <
0.001) and post hoc analysis revealed that Iba1 immu-
noreactivity in the prefrontal cortex was highest in LPS-
treated CX3CR1
-/- mice (Figure 7D iv; P < 0.05). More-
over, in the hippocampus, LPS caused an increase in the
in the proportional area for Iba1
+ microglia (F(1,12) =
5.98, P < 0.05) and was highest in CX3CR1
-/- mice com-
pared to controls (Figure 7F xii, F(1,12) = 9.38, P <
0.05). There was no significant increase in Iba1 immu-
noreactivity in the basolateral amygdala 72 h after LPS
(Figure 7E). Taken together these data indicate that per-
ipheral injection of LPS causes morphological changes
in microglia that are consistent with protracted activa-
tion and this occurs in the absence of increased neuro-
nal death.
Discussion
We have previously reported that stimulation of the per-
ipheral innate immune system with LPS in aged BALB/c
mice causes exaggerated microglial activation with
amplified mRNA and intracellular protein expression of
IL-1b [34] and prolonged reduction in microglial
CX3CR1 expression when compared with microglia of
adult mice [5]. The exaggerated neuroinflammation and
microglial activation was paralleled by prolonged sick-
ness behavior [33,34], impaired working memory [53],
and protracted depression-like behavior [19]. These data
support the hypothesis that impaired CX3CL1/CX3CR1
signalling in microglia is a key contributor to exagger-
ated behavioral impairments in response to LPS. For
example, recovery of social exploratory behavior to base-
line after LPS injection was delayed in CX3CR1
-/- mice
compared to controls (Figure 1). Moreover, peripheral
challenge with LPS caused exaggerated induction of IL-
1b,I D Oa n dK M Om R N Ai nt h eb r a i no fC X 3CR1
-/-
mice (Figures 2). Also, several inflammatory markers
(IL-1b, CD14, and TLR2) remained elevated in microglia
of CX3CR1
-/- mice 24 h after LPS. Furthermore, depres-
sion-like behavior was detectable only in CX3CR1
-/-
mice at 48 and 72 h after LPS injection (Figure 6).
Figure 6 Depression-like behavior was prolonged in CX3CR1
-/-
mice following peripheral LPS injection.C X 3CR1
+/- (Control) or
CX3CR1
-/- (KO) mice were injected i.p. with saline or LPS (0.5 mg/kg)
and A) locomotor activity was determined 24, 48, and 72 h later.
Bars represent the mean ± SEM (n = 10-12). Means with * are
significantly different (P < 0.05) from LPS-treated group. B) Mice
were treated as above and resignation was determined in the tail
suspension test B) 48 (n = 16) and 72 h (n = 10) after injections.
Bars represent the mean ± SEM. Means with * are significantly
different (P < 0.05) from all other treatments.
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-/- mice following peripheral LPS injection.C X 3CR1
+/- (Control) or
CX3CR1
-/- (KO) mice were injected i.p. with saline or LPS (0.5 mg/kg) and A) fluorojade-C staining was determined 72 h later. i) positive control,
ii-v) representative pictures of Fluorojade-C staining in the hippocampus for each group. (B-D) Representative imagines of Iba-1 staining in the B)
prefrontal cortex (PFC) C) basolateral amygdala (BLA), and D) CA1 region of hippocampus (HP). The black boxes over the brain slice images to
the left indicates the region in which images were collected. To evaluate the entire hippocampus (HP), images were collected from the dentate
gyrus, CA1 and CA3 regions (see methods). Proportional area of Iba-1 staining in the E) prefrontal cortex (n = 4), F) basolateral amygdala (n = 3),
and G) hippocampus (n = 3). Bars represent the mean ± SEM. Means with * are significantly different (P < 0.05) from all other treatments.
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sponded with persistent morphological indices of micro-
glial activation in the prefrontal cortex and
hippocampus (Figure 7). Taken together, these data
indicate that a deficiency in microglial regulation by
CX3CR1 is permissive to prolonged neuroinflammation
and behavioral complications after transient activation
of the innate immune system.
It has been previously shown that CX3CR1
-/- mice
have exaggerated microglial activation and neurotoxicity
after repeated i.p. injections of LPS (4 daily injections;
20 ug) [10]. The results of the current study support
these previous studies and show that a single acute
injection of LPS (0.5 mg/kg) is sufficient to cause ampli-
fied (Figure 3) and prolonged microglial activation
(Figures 4&7). With our injection protocol, however,
the extended microglia activation was not associated
with increased neuronal damage in the hippocampus
(Figure 7A).
The present study also shows novel data that the loss
of CX3CR1 was associated with pronounced social with-
drawal (Figure 1A) and extended depression-like beha-
vior (Figure 6B) after an acute injection of LPS. This
protracted resignation behavior after LPS injection was
evident only in the CX3CR1
-/- mice (Figure 6B) and was
not associated with decreased locomotor activity (Figure
6A), exaggerated weight loss, or anorexia (Figures.
1B&1C). The findings of behavioral deficits in CX3CR1-
deficient mice support our previous work with older
BALB/c mice, in which the exaggerated sickness
response after LPS injection [33] was also associated
with prolonged depression-like behavior [19]. These
findings are relevant because they suggest that a deficit
in CX3CR1-mediated regulation of microglia is sufficient
to cause prolonged sickness and depression-like beha-
viors after LPS injection even in the absence of the myr-
iad inflammatory changes associated with aging.
The extended depression-like behavior at 72 h after
LPS was associated with increased activated morphology
of microglia in the prefrontal cortex and hippocampus
(Figure 7B). Because the presence of increased iba1
immunoreactivity is indicative of activation [38], these
data indicate that microglia are active longer in
CX3CR1
-/- than control mice after LPS injection. In
addition, the prefrontal cortex and the hippocampus are
key brain regions associated with the regulation of
mood and depression [54]. Other studies using restraint
stress indicate that Iba1 immunoreactivity was increased
in hippocampus, prefrontal cortex, and amygdala. This
increased microglial activation in these areas was asso-
ciated with anhedonia and depression-like behavior [25].
In the current study, significant increases of Iba1 immu-
noreactivity in the basolateral amygdala were not
detected. This may be because CX3CL1 is highly
expressed in the frontal cortex and hippocampus com-
pared with the amygdala [7,55], indicating that CX3CL1
may have a greater role in regulating microglial activa-
tion in these areas. So, it is plausible that a deficiency of
CX3CR1 could result in brain region-dependent differ-
ences in microglial activation after LPS.
Along with the presence of de-ramified microglia in
LPS-treated CX3CR1
-/- mice, IL-1b protein levels were
higher in the cortex of CX3CR1
-/- mice compared to
controls (Figure 2A). There was also amplified and pro-
longed mRNA expression of IL-1b mRNA in microglia
(Figure 3&4). Based on previous age comparisons with
BALB/c mice, we expected that the majority of inflam-
matory genes examined would be higher in the
CX3CR1
-/- mice. A more specific pattern of activation,
however, was associated with CX3CR1-deficiency. For
example, IL-1b,I D O ,a n dK M Ow e r eh i g h e s ti n
CX3CR1
-/- mice compared to all other groups 4 h after
LPS (Figure 3A,F,G), whereas the LPS-induced increase
of TNFa, TLR2, and CD14 expression was unaffected
by a deficiency of CX3CR1 (Figure 3B-E). This pattern
of activation may explain a key difference observed
between aged mice and CX3CR1
-/- mice. Specifically,
while aged mice show exaggerated anorexia and weight
loss after LPS injection [33], CX3CR1
-/- mice do not
(Figure 1). In previous age comparisons with BALB/c
mice, TNFa w a sh i g h e ri nt h eb r a i no fa g e dm i c ea f t e r
LPS compared with adult mice [56]. This is relevant
because in a previous study, TNFa promoted anorexia
in rodents while IL-1b promoted motivational changes,
including increased social withdrawal behavior [57].
Thus, a specific increase of IL-1b in CX3CR1
-/- mice
without a concomitant exaggeration of TNFa may
enhance the behavioral effects of LPS without causing
exaggerated anorexia and weight loss.
A deficiency of CX3CR1 on microglia also results in
prolonged induction of select inflammatory markers
after LPS injection. For instance, higher mRNA levels of
TLR2 and IL-1b were still present in microglia of
CX3CR1
-/- mice. Thus, CX3CR1-mediated regulation of
IL-1b expression in microglia may play an important
role in the resolution of brain inflammation and sickness
behavior. In support of this notion, CX3CL1/CX3CR1
signalling activates the PI3K/Akt pathway in microglia
[58] and this pathway is essential for fractalkine-signal-
ling to attenuate IL-1b production in mixed glial cul-
tures and microglial activation in aged rats [15]. In
addition, LPS injection significantly decreases CX3CR1
surface expression on microglia; this downregulation is
associated with increased IL-1b production and the pro-
motion of sickness behavior. Recovery from the LPS-
induced microglial activation and sickness behavior is
dependent on restoration of normal CX3CR1 expression
at 24 h after injection [5]. Taken together, we interpret
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promotes a unique cytokine profile after LPS injection
that specifically exaggerates LPS-induced mood and
motivational changes.
Another important finding was that amplified induc-
tion of IDO and KMO was detected in the microglia of
CX3CR1
-/- mice at 4 h after LPS injection. IDO metabo-
lism of TRP into KYN is a key pathway involved in
inflammatory-related depression in humans and in
rodent models. Thus, the ratio of KYN/TRP is a proxy
for IDO enzymatic activity. IDO activity is hypothesized
to contribute to depression by generating neuroactive
metabolites of kynurenine including 3-HK and QUIN.
For instance, in clinical studies, depression is signifi-
cantly higher in patients undergoing therapy with IFNa
a n dt h i si sa s s o c i a t e dw i t hi n c r e a s e dT R Pa n dK Y N
levels in the plasma [59,60] and increased QUIN in the
cerebrospinal fluid [46]. Therefore, we hypothesized that
the increased depression-like behaviors in CX3CR1
-/-
mice would be coupled with exaggerated turnover of
TRP, along with changes in monoamine turnover. Con-
sistent with previous studies using C57BL/6 mice [20],
LPS caused an increased turnover of TRP, DA and 5-
HT in the brain and TRP in the plasma (Figure 5).
There was not, however, an interaction between LPS
and CX3CR1 expression at 24 h. It is possible that the
increased KYN and changes in monoamine turnover
persisted for longer in the CX3CR1
-/- mice at 48 and 72
h after LPS. Because brains from these time points were
analyzed for Iba1, this was not determined.
It is also possible that downstream metabolism of TRP
through the KMO pathway is an important contributor
to prolonged depression. Indeed, KMO activity is selec-
tively increased in the rat brain after LPS injection [61].
A previous study indicated that IDO inhibition with 1-
methyl tryptophan (1-MT) reversed LPS-induced
depression independently of 5-HT turnover [20]. This
same report indicates that peripheral administration of
L-KYN in non-immune stimulated mice mimicked the
depression-like effects of LPS [20]. Thus, although
CX3CR1 deficiency did not affect KYN/TRP ratios, an
exaggerated induction of KMO in microglia of
CX3CR1
-/- mice after LPS (Figure 3) may result in
greater accumulation of 3-HK and QUIN in the brain
and contribute to the extended depression-like behavior
in the TST.
It is important to note that CX3CL1/CX3CR1 signal-
ling events are dependent on the nature of the in-
flammatory stimulus. For instance, experimental
autoimmune encephalomyelitis (EAE) [44,62] and ische-
mia [43,63] are associated with an induction of CX3CL1
and an accumulation of CX3CR1-expressing cells.
Therefore, neuronal or glial release of CX3CL1 may be a
mechanism by which microglia and other CX3CR1
+
immune cells are recruited to damaged areas within the
CNS. Notably, CX3CR1-deficient mice exhibit reduced
leukocyte infiltration after ischemic injury that is asso-
ciated with smaller infarcts and reduced inflammation
after injury [43]. In contrast, CX3CR1-deficient mice
were more susceptible to EAE-related death and hae-
morrhagic brain lesions [44]. The exaggerated EAE was
associated with insufficient recruitment of NK cells into
the brain of CX3CR1
-/- mice. A recent study demon-
strated that CX3CR1
-/- mice show enhanced CX3CL1
expression in the plasma and brain [42]. In the present
study, plasma and cortex levels of CX3CL1 where ele-
vated in the CX3CR1-deficient mice, but were not
affected by LPS (Figure 2C&2D). The lack of an LPS-
induced increase of CX3CL1 argues against the idea that
our LPS stimulus is associated with an influx of
CX3CR1
+ cells that contribute to sickness and depres-
sive behaviors. Furthermore, these data support the idea
that it is the regulation of CX3CR1 on microglia, rather
than LPS-induced changes in CX3CL1, that underlies
neurobehavioral changes after LPS injection [5]. There-
fore, in the context of an acute immune activation, our
data support the idea that CX3CL1-CX3CR1 interactions
function to regulate the activation of microglia sepa-
rately from peripheral interactions.
Conclusions
In conclusion, the present study provides novel evidence
that impaired regulation of microglia through CX3CR1
has profound on subsequent neurobehavioral deficits
after injection of LPS. These data along with our pre-
viously published reports support the hypothesis that
the CX3CR1 is important regulator of microglia.
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